Cancer immunotherapy is a cancer treatment that enhances the immune system’s ability to fight cancer. This therapy is preferable than the old technique because it provides long-term cancer protection, has less side effects, and treats a wider range of cancer. Cancer immunotherapy is used in different types of cancers such as melanoma, prostate cancer, breast cancer, colorectal cancer, lung cancer, head & neck cancer, and more. Immunotherapy works by directing the immune system toward cancer-specific targets, activating the immune system to mobilize the target, and triggering a response capable of destroying cancer cells.
Cancer Immunotherapy Market size was valued at USD 136.4 billion in 2023 and is poised to grow from USD 148.68 billion in 2024 to USD 296.25 billion by 2032, growing at a CAGR of 9.0% during the forecast period (2025-2032).
There are many factors, such as increase in healthcare expenditure, rise in incidence of cancer, surge in access to medical insurance, and surge in technological advancements in cancer treatment therapies expected to propel the growth of the global cancer immunotherapy market. According to statistics given by national cancer institute in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people passed away due to the disease.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/cancer-immunotherapy-market
This surge in the incidences of cancer propel the growth of the industry in the coming years. Increase in awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period. However, the factors such as stringent regulations related to cancer immunotherapy are anticipated to hinder the growth of the cancer immunotherapy market.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Cancer Immunotherapy Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Cancer Immunotherapy Market is segmented by Product Type, Application, Form, End User, Distribution Channel and region.
Based on Product Type, the market is segmented into Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators and Oncolytic Virus.
Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Melanoma, Multiple Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer and Others.
Based on Form, the market is segmented into Intravenous (IV), Intramuscular and Oral.
Based on End User, the market is segmented into Hospitals, Oncology Clinics, Homecare and Others.
Based on Distribution Channel, the market is segmented into Direct Tenders, Retail Sales and Pharmacies.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Cancer Immunotherapy Market – Regional Analysis:
North America dominated the market and accounted for highest market share in 2023, driven by rising patient awareness, high disease burden, proactive government measures, technological advancements, and improvements in healthcare infrastructure. The presence of key players in this region is a key propeller of market growth.
According to Elsevier Ltd. article published in April 2023, The US National Cancer Institute has published its expected national cancer plan, a roadmap, and call to action on improving all stages of care for those suffering from cancer, including prevention, detection, diagnosis during the course of treatment and recovery.
Asia Pacific is anticipated to witness the fastest CAGR in the global market. One of the primary factors driving this growth is an increase in the elderly population, a high number of patients with targeted diseases and improved healthcare infrastructure.
Top Market Players in Cancer Immunotherapy Market are:
Roche Holding AG (Switzerland)
Merck & Co., Inc. (USA)
Bristol Myers Squibb Company (USA)
AstraZeneca plc (UK)
Johnson & Johnson (USA)
Novartis International AG (Switzerland)
Pfizer Inc. (USA)
Amgen Inc. (USA)
Eli Lilly and Company (USA)
Gilead Sciences, Inc. (USA)
Sanofi (France)
Regeneron Pharmaceuticals Inc. (USA)
Bayer AG (Germany)
Takeda Pharmaceutical Company Limited (Japan)
GlaxoSmithKline plc (UK)
Daiichi Sankyo Company, Limited (Japan)
Incyte Corporation (USA)
For a customized report, contact us to request personalization – https://www.skyquestt.com/speak-with-analyst/cancer-immunotherapy-market
Cancer Immunotherapy Market Recent Developments:
In May 2024, The FDA has given its approval to Amgen for an immunotherapy to treat cancer. This immunotherapy is named IIMDELLTRA and can be used to treat adult patients suffering from extensive-stage small lung cancer (ES-SCLC).
In March 2024, Bristol Myers Squibb received approval from the FDA for Breyanzi. Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T cell therapy that helps in treatment of patients suffering from relapsed or refractory small lymphocytic lymphoma and chronic lymphocytic leukemia.
In March 2023, the FDA gave approval of Merck KGAA’s Bavencio. This is an anti-programmed death ligand-1 (PD-L1) antibody therapy that is efficient for treatment of advanced renal cell carcinoma and metastatic Merkel cell carcinoma.
Take Action Now: Secure Your Cancer Immunotherapy Market Today – https://www.skyquestt.com/buy-now/cancer-immunotherapy-market
Forward-Looking Insights
The Cancer Immunotherapy Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
